Nevro Price to Book Ratio 2013-2022 | NVRO
Historical price to book ratio values for Nevro (NVRO) over the last 10 years. The current price to book ratio for Nevro as of February 03, 2023 is 4.34.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Nevro Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-02-03 |
39.79 |
|
4.34 |
| 2022-09-30 |
46.60 |
$9.17 |
5.08 |
| 2022-06-30 |
43.83 |
$6.50 |
6.74 |
| 2022-03-31 |
72.33 |
$6.83 |
10.59 |
| 2021-12-31 |
81.07 |
$8.67 |
9.35 |
| 2021-09-30 |
116.38 |
$9.15 |
12.72 |
| 2021-06-30 |
165.79 |
$10.28 |
16.12 |
| 2021-03-31 |
139.50 |
$10.56 |
13.22 |
| 2020-12-31 |
173.10 |
$11.23 |
15.41 |
| 2020-09-30 |
139.30 |
$11.03 |
12.62 |
| 2020-06-30 |
119.47 |
$10.92 |
10.94 |
| 2020-03-31 |
99.98 |
$6.72 |
14.89 |
| 2019-12-31 |
117.54 |
$6.86 |
17.14 |
| 2019-09-30 |
85.97 |
$6.39 |
13.45 |
| 2019-06-30 |
64.83 |
$6.53 |
9.93 |
| 2019-03-31 |
62.51 |
$7.03 |
8.89 |
| 2018-12-31 |
38.89 |
$8.11 |
4.79 |
| 2018-09-30 |
57.00 |
$8.10 |
7.03 |
| 2018-06-30 |
79.85 |
$8.16 |
9.78 |
| 2018-03-31 |
86.67 |
$8.10 |
10.70 |
| 2017-12-31 |
69.04 |
$8.38 |
8.24 |
| 2017-09-30 |
90.88 |
$8.25 |
11.02 |
| 2017-06-30 |
74.43 |
$8.18 |
9.10 |
| 2017-03-31 |
93.70 |
$8.29 |
11.31 |
| 2016-12-31 |
72.66 |
$8.62 |
8.43 |
| 2016-09-30 |
104.39 |
$8.66 |
12.06 |
| 2016-06-30 |
73.76 |
$8.65 |
8.53 |
| 2016-03-31 |
56.26 |
$8.08 |
6.96 |
| 2015-12-31 |
67.51 |
$8.34 |
8.10 |
| 2015-09-30 |
46.39 |
$8.75 |
5.30 |
| 2015-06-30 |
53.75 |
$9.41 |
5.71 |
| 2015-03-31 |
47.93 |
$6.39 |
7.50 |
| 2014-12-31 |
38.67 |
$6.92 |
5.59 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$1.410B |
$0.387B |
|
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
|
